CompletedNot Applicable

A Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia

United States24 participantsStarted 2022-07-10

Plain-language summary

The purpose of this study is to determine if the Revian Red All LED cap shows potential to be an effective treatment for Central centrifugal cicatricial alopecia (CCCA) by recruiting hair follicles back to anagen growth or by improving inflammation. The primary outcome is to determine if hair loss regression is halted. Secondary outcomes include hair regrowth and alleviation of signs and symptoms of the disease. Participants will be asked to use the Revian Red All LED cap once daily for a 10-minute treatment regimen which is the current androgenetic alopecia recommendation.

Who can participate

Age range18 Years – 65 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Women who are between the age of eighteen years and sixty-five years * Biopsy-proven diagnosis of CCCA Stage II-IV. * Must be on stable treatment without changes (on doxycycline, topical steroids, minoxidil and/or post 8 rounds of intralesional steroids) for at least 3 months Exclusion Criteria: * Subjects with other forms of hair loss that is not CCCA * Prior treatment with light source for alopecia * Males are excluded from this study since the prevalence of CCCA in males is so significantly low that it is difficult to find cases in a clinical setting

What they're measuring

Shape of the Hairline Documented With Photographs

Timeframe: Baseline to month 6

Trial details

NCT IDNCT05759338

SponsorWake Forest University Health Sciences

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-06-19

Results submitted2025-07-24

View on ClinicalTrials.gov More Central Centrifugal Cicatricial Alopecia trials